Is ZBIO or CLDX more profitable?

Celldex Therapeutics' return on equity of -50.72% beat Zenas BioPharma's return on equity. Company Net Margins Return on Equity Return on Assets Zenas BioPharma N/A -99.99% -58.06% Celldex Therapeutics N/A -50.72% -46.59%

Which has stronger earnings and valuation, INVA or ZBIO?

Innoviva has higher revenue and earnings than Zenas BioPharma. Zenas BioPharma is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Innoviva $411.33M 4.24 $271.17M $6.01 3.93 Zenas BioPharma $10M 137.62 -$377.74M -$8.47 N/A

Does the media prefer INVA or ZBIO?

In the previous week, Innoviva had 10 more articles in the media than Zenas BioPharma. MarketBeat recorded 13 mentions for Innoviva and 3 mentions for Zenas BioPharma. Zenas BioPharma's average media sentiment score of 0.90 beat Innoviva's score of -0.52 indicating that Zenas BioPharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Innoviva 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative Zenas BioPharma 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, NVAX or ZBIO?

Novavax has higher revenue and earnings than Zenas BioPharma. Novavax is trading at a lower price-to-earnings ratio than Zenas BioPharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novavax $1.12B 1.30 $440.30M -$0.58 N/A Zenas BioPharma $10M 137.62 -$377.74M -$8.47 N/A

Does the media favor NVAX or ZBIO?

In the previous week, Novavax had 4 more articles in the media than Zenas BioPharma. MarketBeat recorded 7 mentions for Novavax and 3 mentions for Zenas BioPharma. Zenas BioPharma's average media sentiment score of 0.90 beat Novavax's score of 0.41 indicating that Zenas BioPharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novavax 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral Zenas BioPharma 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, MNKD or ZBIO?

MannKind has higher revenue and earnings than Zenas BioPharma. MannKind is trading at a lower price-to-earnings ratio than Zenas BioPharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MannKind $348.97M 3.39 $5.86M -$0.07 N/A Zenas BioPharma $10M 137.62 -$377.74M -$8.47 N/A

Does the media prefer MNKD or ZBIO?

In the previous week, MannKind and MannKind both had 3 articles in the media. MannKind's average media sentiment score of 1.17 beat Zenas BioPharma's score of 0.90 indicating that MannKind is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MannKind 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zenas BioPharma 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Zenas BioPharma (ZBIO) Competitors

$21.80 +1.60 (+7.92%)

Closing price 04:00 PM Eastern

Extended Trading

$21.78 -0.02 (-0.07%)

As of 07:43 PM Eastern

Compare

ZBIO vs. CLDX, BCRX, INVA, NVAX, and MNKD

Should you buy Zenas BioPharma stock or one of its competitors? MarketBeat compares Zenas BioPharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Zenas BioPharma include Celldex Therapeutics (CLDX), BioCryst Pharmaceuticals (BCRX), Innoviva (INVA), Novavax (NVAX), and MannKind (MNKD). These companies are all part of the "biotechnology" industry.

How does Zenas BioPharma compare to Celldex Therapeutics?

Zenas BioPharma (NASDAQ:ZBIO) and Celldex Therapeutics (NASDAQ:CLDX) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, media sentiment, valuation and institutional ownership.

Zenas BioPharma currently has a consensus price target of $44.29, suggesting a potential upside of 103.15%. Celldex Therapeutics has a consensus price target of $49.30, suggesting a potential upside of 45.94%. Given Zenas BioPharma's higher probable upside, equities analysts clearly believe Zenas BioPharma is more favorable than Celldex Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

Zenas BioPharma has a beta of -0.71, indicating that its share price is 171% less volatile than the broader market. Comparatively, Celldex Therapeutics has a beta of 0.95, indicating that its share price is 5% less volatile than the broader market.

Celldex Therapeutics' return on equity of -50.72% beat Zenas BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zenas BioPharma	N/A	-99.99%	-58.06%
Celldex Therapeutics	N/A	-50.72%	-46.59%

Celldex Therapeutics has lower revenue, but higher earnings than Zenas BioPharma. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Zenas BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zenas BioPharma	$10M	137.62	-$377.74M	-$8.47	N/A
Celldex Therapeutics	$1.54M	1,721.68	-$258.76M	-$4.26	N/A

In the previous week, Zenas BioPharma had 3 more articles in the media than Celldex Therapeutics. MarketBeat recorded 3 mentions for Zenas BioPharma and 0 mentions for Celldex Therapeutics. Zenas BioPharma's average media sentiment score of 0.90 beat Celldex Therapeutics' score of 0.00 indicating that Zenas BioPharma is being referred to more favorably in the media.

Company	Overall Sentiment
Zenas BioPharma	Positive
Celldex Therapeutics	Neutral

Summary

Celldex Therapeutics beats Zenas BioPharma on 9 of the 14 factors compared between the two stocks.

How does Zenas BioPharma compare to BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals (NASDAQ:BCRX) and Zenas BioPharma (NASDAQ:ZBIO) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, media sentiment, analyst recommendations and valuation.

BioCryst Pharmaceuticals presently has a consensus target price of $20.70, suggesting a potential upside of 107.54%. Zenas BioPharma has a consensus target price of $44.29, suggesting a potential upside of 103.15%. Given BioCryst Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe BioCryst Pharmaceuticals is more favorable than Zenas BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCryst Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.75
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

BioCryst Pharmaceuticals has a beta of 0.57, indicating that its stock price is 43% less volatile than the broader market. Comparatively, Zenas BioPharma has a beta of -0.71, indicating that its stock price is 171% less volatile than the broader market.

BioCryst Pharmaceuticals has higher revenue and earnings than Zenas BioPharma. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Zenas BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCryst Pharmaceuticals	$874.84M	2.90	$263.86M	-$1.78	N/A
Zenas BioPharma	$10M	137.62	-$377.74M	-$8.47	N/A

Zenas BioPharma has a net margin of 0.00% compared to BioCryst Pharmaceuticals' net margin of -51.71%. BioCryst Pharmaceuticals' return on equity of -76.36% beat Zenas BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioCryst Pharmaceuticals	-51.71%	-76.36%	60.12%
Zenas BioPharma	N/A	-99.99%	-58.06%

85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. 3.8% of BioCryst Pharmaceuticals shares are held by insiders. Comparatively, 22.0% of Zenas BioPharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Zenas BioPharma had 2 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 3 mentions for Zenas BioPharma and 1 mentions for BioCryst Pharmaceuticals. Zenas BioPharma's average media sentiment score of 0.90 beat BioCryst Pharmaceuticals' score of 0.00 indicating that Zenas BioPharma is being referred to more favorably in the news media.

Company	Overall Sentiment
BioCryst Pharmaceuticals	Neutral
Zenas BioPharma	Positive

Summary

BioCryst Pharmaceuticals beats Zenas BioPharma on 10 of the 16 factors compared between the two stocks.

How does Zenas BioPharma compare to Innoviva?

Innoviva (NASDAQ:INVA) and Zenas BioPharma (NASDAQ:ZBIO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, analyst recommendations, institutional ownership and media sentiment.

Innoviva has a net margin of 119.89% compared to Zenas BioPharma's net margin of 0.00%. Innoviva's return on equity of 33.33% beat Zenas BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innoviva	119.89%	33.33%	22.67%
Zenas BioPharma	N/A	-99.99%	-58.06%

Innoviva presently has a consensus target price of $36.20, suggesting a potential upside of 53.13%. Zenas BioPharma has a consensus target price of $44.29, suggesting a potential upside of 103.15%. Given Zenas BioPharma's higher possible upside, analysts plainly believe Zenas BioPharma is more favorable than Innoviva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innoviva	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

In the previous week, Innoviva had 10 more articles in the media than Zenas BioPharma. MarketBeat recorded 13 mentions for Innoviva and 3 mentions for Zenas BioPharma. Zenas BioPharma's average media sentiment score of 0.90 beat Innoviva's score of -0.52 indicating that Zenas BioPharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Innoviva	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative
Zenas BioPharma	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Innoviva has a beta of 0.35, meaning that its stock price is 65% less volatile than the broader market. Comparatively, Zenas BioPharma has a beta of -0.71, meaning that its stock price is 171% less volatile than the broader market.

Innoviva has higher revenue and earnings than Zenas BioPharma. Zenas BioPharma is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innoviva	$411.33M	4.24	$271.17M	$6.01	3.93
Zenas BioPharma	$10M	137.62	-$377.74M	-$8.47	N/A

99.1% of Innoviva shares are held by institutional investors. 2.0% of Innoviva shares are held by company insiders. Comparatively, 22.0% of Zenas BioPharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Innoviva beats Zenas BioPharma on 11 of the 16 factors compared between the two stocks.

How does Zenas BioPharma compare to Novavax?

Novavax (NASDAQ:NVAX) and Zenas BioPharma (NASDAQ:ZBIO) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, risk, institutional ownership, profitability and analyst recommendations.

53.0% of Novavax shares are owned by institutional investors. 1.6% of Novavax shares are owned by insiders. Comparatively, 22.0% of Zenas BioPharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Zenas BioPharma has a net margin of 0.00% compared to Novavax's net margin of -14.73%. Novavax's return on equity of -14.82% beat Zenas BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novavax	-14.73%	-14.82%	1.23%
Zenas BioPharma	N/A	-99.99%	-58.06%

In the previous week, Novavax had 4 more articles in the media than Zenas BioPharma. MarketBeat recorded 7 mentions for Novavax and 3 mentions for Zenas BioPharma. Zenas BioPharma's average media sentiment score of 0.90 beat Novavax's score of 0.41 indicating that Zenas BioPharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novavax	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral
Zenas BioPharma	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Novavax has higher revenue and earnings than Zenas BioPharma. Novavax is trading at a lower price-to-earnings ratio than Zenas BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novavax	$1.12B	1.30	$440.30M	-$0.58	N/A
Zenas BioPharma	$10M	137.62	-$377.74M	-$8.47	N/A

Novavax currently has a consensus price target of $13.00, indicating a potential upside of 46.15%. Zenas BioPharma has a consensus price target of $44.29, indicating a potential upside of 103.15%. Given Zenas BioPharma's stronger consensus rating and higher possible upside, analysts clearly believe Zenas BioPharma is more favorable than Novavax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novavax	3 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.22
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

Novavax has a beta of 2.45, suggesting that its stock price is 145% more volatile than the broader market. Comparatively, Zenas BioPharma has a beta of -0.71, suggesting that its stock price is 171% less volatile than the broader market.

Summary

Novavax and Zenas BioPharma tied by winning 8 of the 16 factors compared between the two stocks.

How does Zenas BioPharma compare to MannKind?

MannKind (NASDAQ:MNKD) and Zenas BioPharma (NASDAQ:ZBIO) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations, institutional ownership and media sentiment.

MannKind has higher revenue and earnings than Zenas BioPharma. MannKind is trading at a lower price-to-earnings ratio than Zenas BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MannKind	$348.97M	3.39	$5.86M	-$0.07	N/A
Zenas BioPharma	$10M	137.62	-$377.74M	-$8.47	N/A

Zenas BioPharma has a net margin of 0.00% compared to MannKind's net margin of -6.63%. MannKind's return on equity of -11.21% beat Zenas BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MannKind	-6.63%	-11.21%	-3.92%
Zenas BioPharma	N/A	-99.99%	-58.06%

In the previous week, MannKind and MannKind both had 3 articles in the media. MannKind's average media sentiment score of 1.17 beat Zenas BioPharma's score of 0.90 indicating that MannKind is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MannKind	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zenas BioPharma	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MannKind presently has a consensus target price of $8.97, suggesting a potential upside of 134.48%. Zenas BioPharma has a consensus target price of $44.29, suggesting a potential upside of 103.15%. Given MannKind's stronger consensus rating and higher probable upside, equities analysts clearly believe MannKind is more favorable than Zenas BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MannKind	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

MannKind has a beta of 1.13, meaning that its share price is 13% more volatile than the broader market. Comparatively, Zenas BioPharma has a beta of -0.71, meaning that its share price is 171% less volatile than the broader market.

49.6% of MannKind shares are held by institutional investors. 2.6% of MannKind shares are held by company insiders. Comparatively, 22.0% of Zenas BioPharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

MannKind beats Zenas BioPharma on 11 of the 15 factors compared between the two stocks.

Get Zenas BioPharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZBIO vs. The Competition

Export

Metric	Zenas BioPharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.28B	$3.49B	$6.74B	$12.32B
Dividend Yield	N/A	2.28%	2.68%	5.88%
P/E Ratio	-2.57	20.50	25.39	23.96
Price / Sales	137.62	328.65	530.17	107.90
Price / Cash	N/A	130.96	45.29	53.76
Price / Book	4.83	8.26	10.76	6.41
Net Income	-$377.74M	$23.91M	$3.56B	$337.14M
7 Day Performance	17.33%	3.05%	1.37%	-0.48%
1 Month Performance	14.92%	2.40%	0.81%	0.49%
1 Year Performance	117.56%	56.35%	30.53%	28.16%

Zenas BioPharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZBIO Zenas BioPharma	3.7756 of 5 stars	$21.80 +7.9%	$44.29 +103.1%	+113.3%	$1.28B	$10M	N/A	N/A	Gap Up
CLDX Celldex Therapeutics	1.6372 of 5 stars	$32.32 +0.6%	$49.30 +52.5%	+61.7%	$2.52B	$1.54M	N/A	150
BCRX BioCryst Pharmaceuticals	2.1941 of 5 stars	$8.92 -1.5%	$20.70 +132.1%	-6.1%	$2.30B	$874.84M	N/A	530	Options Volume
INVA Innoviva	3.7639 of 5 stars	$22.61 +0.8%	$36.20 +60.1%	+13.2%	$1.65B	$411.33M	3.76	100	Trending News Analyst Forecast Analyst Revision
NVAX Novavax	1.8499 of 5 stars	$9.20 -0.1%	$13.00 +41.3%	+42.6%	$1.51B	$1.12B	N/A	1,990	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ZBIO) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Zenas BioPharma (ZBIO) Competitors

ZBIO vs. CLDX, BCRX, INVA, NVAX, and MNKD

How does Zenas BioPharma compare to Celldex Therapeutics?

Summary

How does Zenas BioPharma compare to BioCryst Pharmaceuticals?

Summary

How does Zenas BioPharma compare to Innoviva?

Summary

How does Zenas BioPharma compare to Novavax?

Summary

How does Zenas BioPharma compare to MannKind?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZBIO vs. The Competition

Zenas BioPharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Zenas BioPharma (ZBIO) Competitors

ZBIO vs. CLDX, BCRX, INVA, NVAX, and MNKD

How does Zenas BioPharma compare to Celldex Therapeutics?

Do analysts prefer ZBIO or CLDX?

Which has more risk and volatility, ZBIO or CLDX?

Is ZBIO or CLDX more profitable?

Which has preferable valuation and earnings, ZBIO or CLDX?

Does the media prefer ZBIO or CLDX?

Summary

How does Zenas BioPharma compare to BioCryst Pharmaceuticals?

Do analysts recommend BCRX or ZBIO?

Which has more risk and volatility, BCRX or ZBIO?

Which has stronger valuation and earnings, BCRX or ZBIO?

Is BCRX or ZBIO more profitable?

Do institutionals & insiders have more ownership in BCRX or ZBIO?

Does the media favor BCRX or ZBIO?

Summary

How does Zenas BioPharma compare to Innoviva?

Is INVA or ZBIO more profitable?

Do analysts prefer INVA or ZBIO?

Does the media prefer INVA or ZBIO?

Which has more risk & volatility, INVA or ZBIO?

Which has stronger earnings and valuation, INVA or ZBIO?

Do insiders and institutionals hold more shares of INVA or ZBIO?

Summary

How does Zenas BioPharma compare to Novavax?

Do institutionals & insiders hold more shares of NVAX or ZBIO?

Is NVAX or ZBIO more profitable?

Does the media favor NVAX or ZBIO?

Which has higher earnings and valuation, NVAX or ZBIO?

Do analysts rate NVAX or ZBIO?

Which has more risk & volatility, NVAX or ZBIO?

Summary

How does Zenas BioPharma compare to MannKind?

Which has higher earnings & valuation, MNKD or ZBIO?

Is MNKD or ZBIO more profitable?

Does the media prefer MNKD or ZBIO?

Do analysts prefer MNKD or ZBIO?

Which has more volatility and risk, MNKD or ZBIO?

Do institutionals and insiders hold more shares of MNKD or ZBIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZBIO vs. The Competition

Zenas BioPharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools